NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup

Retsky, Michael; Rogers, Rick A.; Demicheli, Romano; Hrushesky, William J. M.; Gukas, Isaac D.; Vaidya, JS; Baum, Michael; Forget, Patrice; DeKock, M; Pachmann, Katharina

doi:10.1007/s10549-012-2094-5

Cited by 95 publications

(62 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This effect seen on metastasis is similar to the reduction of metastatic disease observed in human studies (Rothwell et al 2012b ). Similarly when syngeneic orthotopic breast cancer cell lines were injected into the fat pads of adult mice, those treated with a COX2 inhibitor showed signifi cantly fewer and smaller volume lung metastases, an action dependent on the M2 polarization of macrophages in the model (Retsky et al 2012 ). Data obtained from patients treated with mastectomy for breast cancer has revealed that use of perioperative NSAIDs signifi cantly improved disease free survival during the fi rst 5 years.…”

Section: Observational Studies Highlighting the Potential Role Of Nonsupporting

confidence: 73%

Inflammatory Dysregulation and Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Steele

Jamieson

Carter

2014

Stress Response Pathways in Cancer

View full text Add to dashboard Cite

The association between infl ammation and cancer has been established for well over 100 years. Only now are we beginning to unravel the complexities of the infl ammatory mechanisms that are integral to the initiation and progression of cancer. From large observational studies, to in-depth mechanistic in vivo modelling studies every aspect of infl ammatory dysregulation is being examined. Better understanding of the cellular and molecular processes mediating cancer associated infl ammation and the vital role it plays in cancer progression have begun to be exploited for therapeutic benefi t. Here we describe the rationale for study of infl ammation in cancer, provide an overview of our current understanding of infl ammatory dysregulation in cancer, and assess the possible therapeutic avenues to be explored. We use pancreatic cancer, one of the most biologically diverse and aggressive examples to inform our discussion.

show abstract

Section: Observational Studies Highlighting the Potential Role Of Nonsupporting

confidence: 73%

Inflammatory Dysregulation and Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Steele

Jamieson

Carter

2014

Stress Response Pathways in Cancer

View full text Add to dashboard Cite

show abstract

“…Recent studies have reported a correlation between systemic inflammation and cancer, suggesting that the immune response is crucial for cancer growth, progression, and treatment resistance, and that it is even associated with 26 demonstrated that perioperative use of the nonsteroidal anti-inflammatory drug ketorolac suppresses early breast cancer relapse, especially in patients with tnbc. Ono et al 27 reported that levels of tumour-infiltrating lymphocytes are significantly higher in patients with tnbc and that high levels of tumour infiltrating lymphocytes are related to improved survival and pcr in the neoadjuvant setting.…”

Section: Discussionmentioning

confidence: 99%

Neutrophil–Lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Studies have also evaluated NSAIDs given in conjunction with chemotherapeutic agents to improve response rates to chemotherapy with success [45,46,49,50]. However, the majority of studies on the perioperative use of NSAIDs and their effects on cancer recurrence has been limited in sample size, retrospective reviews of human data [59,60], and animal studies [61].…”

Section: Nonsteroidal Anti-inflammatory Drugsmentioning

confidence: 99%

Cancer Recurrence and Regional Anesthesia: The Theories, the Data, and the Future in Outcomes

Le-Wendling

Nin

Capdevila³

2016

Pain Med

View full text Add to dashboard Cite

Objective. More than one million people each year in the United States are diagnosed with cancer. Surgery is considered curative, but the perioperative phase represents a vulnerable period for residual disease to spread. Regional anesthesia has been proposed to reduce the incidence of recurrence by attenuating the sympathetic nervous system's response during surgery, reducing opioid requirements thus diminishing their immunosuppressant effects, and providing antitumor and antiinflammatory effects directly through systemic local anesthetic action. In this article, we present a description of the perioperative period, a summary of the proposed hypotheses and available literature on the effects of regional anesthesia on cancer recurrence, and put regional anesthesia in context in regard to its potential role in reducing cancer recurrence during the perioperative period.Methods. A literature review was conducted through PubMed by examining the following topics: effects of surgery on tumor progression, roles of multiple perioperative variables (analgesics, hypothermia, blood transfusion, beta-blockade) in cancer recurrence, and available in vitro, animal, and human studies regarding the effects of regional anesthesia on cancer recurrence.Results. in vitro, animal and human retrospective studies suppport the hypothesis that in certain types of cancer, regional anesthesia may be associated with lower recurrence rates. A few well-planned human randomized clinical trials are currently under way that may provide more solid evidence to substantiate or refute the benefits of regional anesthesia in reducing cancer recurrence.Conclusions. The benefits of regional anesthesia in reducing cancer recurrence have a sound theoretical basis and, in certain cancers, are supported by the existing body of literature. This article outlines the current state of our knowledge on the relationship between cancer progression and regional analgesia.

show abstract

NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup

Cited by 95 publications

References 28 publications

Inflammatory Dysregulation and Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Inflammatory Dysregulation and Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Neutrophil–Lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer

Cancer Recurrence and Regional Anesthesia: The Theories, the Data, and the Future in Outcomes

Contact Info

Product

Resources

About